Schizophrenia: Neural mechanisms for novel therapies

被引：49
作者：
Sawa, A
Snyder, SH
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
来源：
MOLECULAR MEDICINE | 2003年 / 9卷 / 1-2期
关键词：
D O I：
10.1007/BF03402101
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated "negative" symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the alpha7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenic has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.
引用
收藏
页码：3 / 9
页数：7
相关论文
共 44 条
[21]   Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia [J].
Kapur, S ;
Remington, G .
ANNUAL REVIEW OF MEDICINE, 2001, 52 :503-517
[22]   SUBANESTHETIC EFFECTS OF THE NONCOMPETITIVE NMDA ANTAGONIST, KETAMINE, IN HUMANS - PSYCHOTOMIMETIC, PERCEPTUAL, COGNITIVE, AND NEUROENDOCRINE RESPONSES [J].
KRYSTAL, JH ;
KARPER, LP ;
SEIBYL, JP ;
FREEMAN, GK ;
DELANEY, R ;
BREMNER, JD ;
HENINGER, GR ;
BOWERS, MB ;
CHARNEY, DS .
ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) :199-214
[23]   Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia [J].
Leonard, S ;
Gault, J ;
Hopkins, J ;
Logel, J ;
Vianzon, R ;
Short, M ;
Drebing, C ;
Berger, R ;
Venn, D ;
Sirota, P ;
Zerbe, G ;
Olincy, A ;
Ross, RG ;
Adler, LE ;
Freedman, R .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (12) :1085-1096
[24]   The "incredible shrinking" P50 event-related potential [J].
Light, GA ;
Braff, DL .
BIOLOGICAL PSYCHIATRY, 1998, 43 (12) :918-920
[25]   Cell surface heparan sulfate and its roles in assisting viral infectious [J].
Liu, J ;
Thorp, SC .
MEDICINAL RESEARCH REVIEWS, 2002, 22 (01) :1-25
[26]   A review of the effects of nicotine on schizophrenia and antipsychotic medications [J].
Lyon, ER .
PSYCHIATRIC SERVICES, 1999, 50 (10) :1346-1350
[27]   Disruption of two novel genes by a translocation co-segregating with schizophrenia [J].
Millar, JK ;
Wilson-Annan, JC ;
Anderson, S ;
Christie, S ;
Taylor, MS ;
Semple, CAM ;
Devon, RS ;
St Clair, DM ;
Muir, WJ ;
Blackwood, DHR ;
Porteous, DJ .
HUMAN MOLECULAR GENETICS, 2000, 9 (09) :1415-1423
[28]   Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex [J].
Mirnics, K ;
Middleton, FA ;
Marquez, A ;
Lewis, DA ;
Levitt, P .
NEURON, 2000, 28 (01) :53-67
[29]   Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia [J].
Mirnics, K ;
Middleton, FA ;
Stanwood, GD ;
Lewis, DA ;
Levitt, P .
MOLECULAR PSYCHIATRY, 2001, 6 (03) :293-301
[30]   Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats [J].
Moghaddam, B ;
Adams, BW .
SCIENCE, 1998, 281 (5381) :1349-1352
12345